Thursday, December 12, 2024
wellness India Expo
Home Tags Respiratory

Tag: Respiratory

Lupin appoints Claus Jepsen as President, Global Specialty

Claus joins Lupin from Takeda Pharmaceuticals, where he led the Global Strategy for Rare Diseases

Aerogen & IARC sign strategic MoU to transform respiratory care in...

The signing of this MoU underscores a long-term commitment to addressing India’s growing respiratory care needs and sets the stage for transformative improvements in the field

Respiratory disease with 15.3% burden highest in India, reveals study by...

Asthma contributes 10% of all respiratory diseases and has seen a more moderate increase over the past 10 years

Moderna receives U.S. FDA approval for RSV Vaccine mRESVIA

mRESVIA is Moderna's second approved product and the only RSV vaccine available in single-dose pre-filled syringes

Tobacco epidemic grips Indian youth: KPMG report

KPMG Report Exposes Consumption of Tobacco among 49% of Young Adults, Calls for Collaborative Tobacco Control Measures

Nasovac-S4 offers defence against recent surge in respiratory illnesses, say experts

NASOVAC-S4, India’s first exclusive needle-free flu vaccine, is administered through the nasal route, offering a non-invasive and painless alternative to traditional injections

World COPD Day: Alkem Healthy Lungs Initiative promotes importance of inhalation...

The countrywide initiative aims to spread awareness, educate the public & ensure that no one is left behind in the fight against respiratory diseases

AstraZeneca India gets CDSCO approval for Palivizumab, a preventive therapy for...

In India, Respiratory Syncytial Virus is the most common cause of hospitalization in children <1 years old

Digital respiratory devices market worth to be US$ 900 Billion by...

The increased frequency of respiratory disorders has pushed for advancements in the production of breathing equipment

Zydus’s COVID-19 drug ‘Virafin’ gets DCGI nod

91.15% of patients treated with PegIFN were RT PCR negative by day 7. A single dose of the antiviral Virafin administered subcutaneously early on shows significant clinical and virological improvement in moderate COVID-19 adult patients.......................